Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1991;23(1):13-25.
doi: 10.1007/BF02549723.

Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence

Affiliations
Case Reports

Metastatic renal cell carcinoma (RCC): spontaneous regression, long-term survival and late recurrence

W de Riese et al. Int Urol Nephrol. 1991.

Abstract

We report 4 cases of metastatic renal cell carcinoma (RCC) with long-term survival either following radical nephrectomy alone or in combination with radio- or hormonal therapy. Two patients with lymph node metastases showed a long-term survival of 12 or more years following radical tumour nephrectomy (with lymphadenectomy) and radiotherapy. One of them exhibited a histologically proven tumour recurrence nearly 12 years after primary surgical treatment and died shortly later; the other one is still without any evidence of metastatic disease. Two other patients exhibited spontaneous regression of pulmonary metastases: one regression occurred after radical tumour nephrectomy alone, the other one after successful primary hormonal treatment and subsequent radical tumour nephrectomy. The following important aspects are emphasized: 1. Renal cell carcinoma is a very unpredictable tumour. Once the diagnosis of renal cell carcinoma is proved, a patient can never be considered cured. 2. Although adjuvant palliative nephrectomy has produced contradictory results in several reports, radical tumour nephrectomy either alone or in combination with other adjuvant therapies such as radiotherapy, hormonal or immunological treatment, can be worthwhile. Cases with long-term survival and spontaneous regression of distant metastases are proof of this. Besides, if carefully selected, the mortality rate of different adjuvant therapies is not significantly higher in patients with metastatic disease than in patients without metastases. The world literature on this subject is reviewed.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Urology. 1982 Aug;20(2):177-81 - PubMed
    1. JAMA. 1976 Aug 23;236(8):950-1 - PubMed
    1. Eur Urol. 1979;5(2):94-6 - PubMed
    1. Br J Urol. 1973 Jun;45(3):237-57 - PubMed
    1. J Urol. 1978 Aug;120(2):148-52 - PubMed

Publication types

LinkOut - more resources